BRCA1 and breast carcinoma: Incorporation of computational chemistry has revolutionized the drug development paradigm for PARP1 inhibitors, allowing for unmatched accuracy and efficacy in designing therapies for breast cancer, particularly in BRCA1/2-mutated tumors [25].